{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:40:35Z","timestamp":1793356835020,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101281","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:39:47Z","timestamp":1789832387000},"page":"101281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["36.25\u00a0Gy versus 40\u00a0Gy in five fractions of curative stereotactic body radiotherapy for prostate cancer: a propensity score-matched analysis"],"prefix":"10.1016","volume":"62","author":[{"given":"Hideomi","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subaru","family":"Sawayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanano","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Katano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101281_bb0005","unstructured":"https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/kakutei23\/index.html 2026."},{"key":"10.1016\/j.ctro.2026.101281_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2026.101281_bb0015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensitymodulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0020","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.30101","article-title":"Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer","volume":"122","author":"Halpern","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2026.101281_bb0025","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101281_bb0030","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fonc.2017.00157","article-title":"Prostate-specific antigen 5 years following stereotactic body radiation therapy for low and intermediate-risk prostate cancer: an ablative procedure?","volume":"7","author":"Kataria","year":"2017","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101281_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2022","key":"10.1016\/j.ctro.2026.101281_bb0050","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): prostate Cancer","volume":"3","author":"National Comprehensive Cancer Network\u00ae","year":"2022","journal-title":"Version"},{"key":"10.1016\/j.ctro.2026.101281_bb0055","series-title":"WHO disability assessment schedule 2.0 (WHODAS 2.0) (report). WHO","year":"2014"},{"issue":"3","key":"10.1016\/j.ctro.2026.101281_bb0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2006.05.012","article-title":"Guidelines for primary radiotherapy of patients with prostate cancer","volume":"79","author":"Boehmer","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13014-015-0351-6","article-title":"Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer","volume":"10","author":"Gurka","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101281_bb0075","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate Cancer: a systematic review and Meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2026.101281_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13014-022-02061-y","article-title":"Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study","volume":"17","author":"Yamashita","year":"2022","journal-title":"Radiat Oncol"},{"issue":"34","key":"10.1016\/j.ctro.2026.101281_bb0085","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate Cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101281_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101281_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101281_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00936","article-title":"Prostate SBRT: comparison the efficacy and toxicity of two different dose fractionation schedules","volume":"10","author":"Fuller","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101281_bb0105","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/cancers16081472","article-title":"In curative stereotactic body radiation therapy for prostate cancer, there is a high possibility that 45 Gy in five fractions will not be tolerated without a hydrogel spacer","volume":"16","author":"Sawayanagi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101281_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2021.03.025","article-title":"A multi-institutional phase 2 trial of high-dose ASbR for prostate cancer using rectal spacer","volume":"111","author":"Folkert","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101281_bb0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2012.12.019","article-title":"A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes","volume":"87","author":"Song","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2026.101281_bb0120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2026.101281_bb0125","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2026.101281_bb0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-019-1346-5","article-title":"Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes","volume":"14","author":"Hwang","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0135","first-page":"1","article-title":"Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: summary of level 1 evidence and current gaps in knowledge","volume":"37","author":"Baude","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101281_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of highrisk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2026.101281_bb0145","article-title":"Enhancing androgen deprivation therapy (ADT) integration in prostate cancer: insights for stereotactic body radiotherapy (SBRT) and brachytherapy modalities","volume":"45","author":"Gomez-Iturriaga","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2026.101281_bb0150","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101281_bb0155","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"87","author":"Kishan","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101281_bb0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for Oligorecurrent metastatic prostate Cancer (SATURN): primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600176X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600176X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:05:52Z","timestamp":1793354752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082600176X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":32,"alternative-id":["S240563082600176X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101281","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"36.25\u00a0Gy versus 40\u00a0Gy in five fractions of curative stereotactic body radiotherapy for prostate cancer: a propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101281"}}